Based on the current evidence, cabergoline appears to be a highly effective treatment option for patients with hyperprolactinemia compared to bromocriptine; however, our results did not show a statistically significant difference in efficacy between these agents. Normalizing prolactin levels appears to be necessary to relieve the inhibitory effect on testosterone production. Nevertheless, we observed an upward trend in testosterone levels following treatment with dopamine receptor agonists, although the change was not statistically significant (Fig 1B). Elevated prolactin levels can lead to endothelial dysfunction, characterized by impaired NO production, which is essential for vascular relaxation and increased blood flow to the penis. Hyperprolactinemia means you have high levels of prolactin in your blood. People assigned male at birth have lower levels of prolactin. Furthermore, cabergoline treatment has been found to improve sexual drive and function, as well as positively impact the perception of the refractory period. In evaluating a man for low testosterone, doctors often check thyroid function tests, because fatigue, low mood, and sexual dysfunction can also stem from thyroid imbalances. In summary, monitoring estradiol is often part of managing testosterone therapy, and addressing it is important for comfort and safety. Many specialists do measure estradiol levels in men receiving testosterone to ensure they’re not excessively high. Because of the complex feedback loops in the endocrine system, introducing testosterone therapy can affect several other hormones and health parameters. A hematocrit above ~52-54% is concerning because it may thicken the blood and increase the risk of clotting problems (like stroke or thromboembolism). This is why in the U.S., testosterone prescriptions often come with the plan for regular PSA tests. Also, if severe urinary symptoms develop (difficulty urinating, etc.), the dose might need reduction or a BPH medication added. Most studies have not shown TRT to significantly increase prostate cancer incidence, but vigilance is maintained. This is to screen for any occult prostate cancer, since adding testosterone could theoretically stimulate an existing cancer. Overall, DHT is part of the testosterone ecosystem, and its effects are mostly "side effects" we monitor (skin and prostate changes). An alternative strategy is lowering the testosterone dose if possible. All patients were treated with bromocriptine, except for five patients who were intolerant to bromocriptine switched to cabergoline. Testosterone is converted by 5α-reductase into the most potent androgen dihydrotestosterone (DHT), which binds to androgen receptor (AR) to exert its promotive effects on penile erection and libido . Pituitary height reduction may serve as an important diagnostic marker and indicator of treatment effectiveness. Eighteen patients received bromocriptine, whereas five patients received cabergoline. Primary complaints at diagnosis included low libido, gynecomastia, impotence, and erectile dysfunction. The explosion in the use of testosterone in the past decade is multifactorial in its etiology, including the increased use of direct-to-consumer advertising, which has resulted in greater patient knowledge and demand; relaxation of the indications for testosterone prescribing by clinicians; and the establishment of clinical care centers devoted to men's health, testosterone treatment, and anti-aging strategies. Clinicians may use aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or a combination thereof in men with testosterone deficiency desiring to maintain fertility. Testosterone therapy should not be commenced for a period of three to six months in patients with a history of a cardiovascular events. The long-term impact of exogenous testosterone on spermatogenesis should be discussed with patients who are interested in future fertility. Low or high levels of prolactin may require no medical treatment. In some cases, your doctor may prescribe medicine to lower prolactin levels. One study found that a prolactin level of less than 5 ng/mL in women of reproductive age may increase a woman’s risk of metabolic syndrome. Lower levels of prolactin usually do not need medical treatment. Prolactin is produced by the pituitary gland, a small structure located at the base of the brain. However, prolactin, another essential hormone, plays a crucial role that often goes unnoticed. You should see an endocrinologist for prolactinoma management.
